Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.

Bruna R, Benedetti F, Boccomini C, Patti C, Barbui AM, Pulsoni A, Musso M, Liberati AM, Gini G, Castellino C, Rossini F, Ciceri F, Rota-Scalabrini D, Stelitano C, Di Raimondo F, Tucci A, Devizzi L, Zoli V, Zallio F, Narni F, Dondi A, Parvis G, Semenzato G, Lanza F, Perrone T, Angrilli F, Billio A, Gueli A, Mantoan B, Rambaldi A, Gianni AM, Corradini P, Passera R, Ladetto M, Tarella C.

Haematologica. 2019 Nov;104(11):2241-2248. doi: 10.3324/haematol.2018.209932. Epub 2019 Apr 11.

2.

Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.

Della Starza I, Cavalli M, De Novi LA, Genuardi E, Mantoan B, Drandi D, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network.

Hematol Oncol. 2019 Oct;37(4):368-374. doi: 10.1002/hon.2652. Epub 2019 Aug 16.

PMID:
31325190
3.

Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia.

Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jiménez C, Guerrini F, Schirico ML, Mantoan B, Muccio V, Lia G, Zaccaria GM, Omedè P, Passera R, Orsucci L, Benevolo G, Cavallo F, Galimberti S, Sanz RG, Boccadoro M, Ladetto M, Ferrero S.

Haematologica. 2018 Jun;103(6):1029-1037. doi: 10.3324/haematol.2017.186528. Epub 2018 Mar 22.

4.

Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis.

Genuardi E, Barbero D, Dogliotti I, Mantoan B, Drandi D, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, Ferrero S; Fondazione Italiana Linfomi (FIL) MRD Network.

Int J Lab Hematol. 2018 Apr;40(2):201-208. doi: 10.1111/ijlh.12766. Epub 2017 Dec 4.

PMID:
29205868
5.

Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.

Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E, Monitillo L, Cerri M, Ruggeri M, Omede P, Deambrogi C, De Paoli L, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S.

Br J Haematol. 2018 Jun;181(5):693-695. doi: 10.1111/bjh.14681. Epub 2017 Apr 2. No abstract available.

PMID:
28369711
6.

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M.

J Mol Diagn. 2015 Nov;17(6):652-60. doi: 10.1016/j.jmoldx.2015.05.007. Epub 2015 Aug 28.

PMID:
26319783
7.

Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.

Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M.

Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14.

8.

Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network.

Mannu C, Gazzola A, Ciabatti E, Fuligni F, Cavalli M, Della Starza I, Genuardi E, Mantoan B, Monitillo L, Del Giudice I, Ladetto M, Gaidano G, Sabattini E, Pileri SA, Galimberti S, Piccaluga PP; Fondazione Italiana Linfomi Minimal Residual Disease Network.

Leuk Lymphoma. 2016 Feb;57(2):400-410. doi: 10.3109/10428194.2014.914199. Epub 2015 Mar 11.

PMID:
25115509
9.

Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance.

Della Starza I, Cavalli M, Del Giudice I, Barbero D, Mantoan B, Genuardi E, Urbano M, Mannu C, Gazzola A, Ciabatti E, Guarini A, Foà R, Galimberti S, Piccaluga P, Gaidano G, Ladetto M, Monitillo L.

Hematol Oncol. 2014 Sep;32(3):133-8. doi: 10.1002/hon.2095. Epub 2013 Nov 19.

PMID:
24254547
10.

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.

Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi.

Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1.

11.

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.

Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S, Bernocco E, Caracciolo D, Ruella M, Drandi D, Zanni M, Renna F, Lobetti Bodoni C, Gueli A, Passera R, Musto P, Boccadoro M, Tarella C, Ladetto M.

Ann Hematol. 2013 Nov;92(11):1503-11. doi: 10.1007/s00277-013-1797-y. Epub 2013 Jun 5.

PMID:
23737092
12.

Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.

Lobetti-Bodoni C, Mantoan B, Monitillo L, Genuardi E, Drandi D, Barbero D, Bernocco E, Boccadoro M, Ladetto M.

Ther Adv Hematol. 2013 Jun;4(3):189-98. doi: 10.1177/2040620713480522.

13.

Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.

Ferrero S, Drandi D, Mantoan B, Ghione P, Omedè P, Ladetto M.

Hematol Oncol. 2011 Dec;29(4):167-76. doi: 10.1002/hon.989. Epub 2011 Apr 2. Review.

PMID:
22678691
14.

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, Rossi D, Barbiero S, Mantoan B, Mantella E, Zanni M, Ghione P, Larocca A, Passera R, Bertoni F, Gattei V, Forconi F, Laurenti L, Del Poeta G, Marasca R, Cortelazzo S, Gaidano G, Palumbo A, Boccadoro M, Ladetto M.

Haematologica. 2012 Jun;97(6):849-53. doi: 10.3324/haematol.2011.052852. Epub 2011 Dec 29.

15.

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, Astolfi M, Matteucci P, Guidetti A, Mantoan B, Bodoni CL, Zanni M, Boccadoro M, Gianni AM, Tarella C.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1270-6.

16.

Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations.

Ladetto M, Mantoan B, De Marco F, Drandi D, Aguzzi C, Astolfi M, Vallet S, Ricca I, Dell' Aquila M, Pagliano G, Monitillo L, Pollio B, Santo L, Cristiano C, Rocci A, Francese R, Bodoni CL, Borchiellini A, Schinco P, Boccadoro M, Tarella C.

Exp Hematol. 2006 Dec;34(12):1680-6.

PMID:
17157165
17.

Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.

Compagno M, Mantoan B, Astolfi M, Boccadoro M, Ladetto M.

Methods Mol Med. 2005;113:145-63.

PMID:
15968100
18.

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, Santo L, Drandi D, Bertola A, Falco P, Cavallo F, Ricca I, De Marco F, Mantoan B, Bode-Lesniewska B, Pagliano G, Francese R, Rocci A, Astolfi M, Compagno M, Mariani S, Godio L, Marino L, Ruggeri M, Omedè P, Palumbo A, Boccadoro M.

Blood. 2005 Jun 15;105(12):4784-91. Epub 2005 Feb 24.

PMID:
15731178
19.

Differences in extracellular enzymatic activity between Candida dubliniensis and Candida albicans isolates.

Vidotto V, Pontón J, Aoki S, Quindós G, Mantoan B, Pugliese A, Ito-Kuwa S, Nakamura K.

Rev Iberoam Micol. 2004 Jun;21(2):70-4.

20.

Adherence of Candida albicans and Candida dubliniensis to buccal and vaginal cells.

Vidotto V, Mantoan B, Pugliese A, Pontón J, Quindós G, Aoki S, Ito-Kuwa S.

Rev Iberoam Micol. 2003 Jun;20(2):52-4.

21.

Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders.

Ladetto M, Compagno M, Ricca I, Pagano M, Rocci A, Astolfi M, Drandi D, di Celle PF, Dell'Aquila M, Mantoan B, Vallet S, Pagliano G, De Marco F, Francese R, Santo L, Cuttica A, Marinone C, Boccadoro M, Tarella C.

Blood. 2004 Jun 15;103(12):4644-9. Epub 2004 Feb 26.

22.

Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone.

Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, Vallet S, dell'Aquila M, Alfarano A, Rossatto P, Rocci A, Vitolo U, Corradini P, Boccadoro M, Tarella C.

Exp Hematol. 2003 Sep;31(9):784-8.

PMID:
12962724

Supplemental Content

Loading ...
Support Center